HYPERRHO S/D MINI-DOSE Rx
Generic Name and Formulations:
Rho(D) immune globulin human; 250 IU; per syringe; soln for IM inj.; preservative-free; latex-free.
Grifols Biologicals, Inc.
Indications for HYPERRHO S/D MINI-DOSE:
Prevention of isoimmunization of Rho(D) negative women during spontaneous or induced abortion of ≤12 weeks' gestation when mother is not sensitized to Rho(D) antigen and father is not known to be Rho(D) negative.
Postabortion or miscarriage of up to 12 weeks gestation: 1 syringe IM within 3hrs of spontaneous or induced abortion or within 72hrs following termination of pregnancy.
Contains human plasma; monitor for possible infection transmission. IgA deficiency. Pregnancy (Cat.C).
Avoid live vaccines within 3 months.
Local or infusion reactions.
Report all infections suspected to be transmitted by HyperRHO S/D to (800) 520-2807.
Full dose (Single-dose prefilled syringe)—1; Mini dose (Single-dose prefilled syringe)—10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|